BOSTON — In this Healio Video Perspective from the ASCRS meeting, John Sheets, PhD, of Pantheon Vision previews a product designed to address unmet needs in corneal blindness compared with the standard of care of transplantation.According to Sheets, th…
VIDEO: Miebo improves dry eye signs, symptoms with ‘unprecedented’ safety
In this Healio Video Perspective from the ASCRS meeting, John D. Sheppard, MD, MMSc, FACS, discusses a post hoc analysis of two clinical trials investigating Miebo for the treatment of dry eye disease.Miebo (perfluorohexyloctane ophthalmic solution, Ba…
LENSRXLAB Introduces Groundbreaking Vision Benefits Platform Catered to Diabetic Individuals
PHILADELPHIA–(BUSINESS WIRE)– #benefits–LENSRXLAB, a leading provider of diabetic, safety, and dress eyewear, announces the launch of its Supplemental Vision Benefits Platform for Diabetics, aiming to revolutionize vision care. Founded by a Military…
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Frontiers in Ophthalmology published statistically significant res…
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to …
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the…